A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Purpose

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed. Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being developed for the treatment of UC in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based maintenance regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Around 120 pediatric participants with UC will be enrolled at around 80 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Condition

  • Ulcerative Colitis

Eligibility

Eligible Ages
Between 2 Years and 17 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Active ulcerative colitis (UC) with an modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central reader). - Demonstrated intolerance or inadequate response (IR) to one or more of the following categories of drugs: aminosalicylates (except in countries where failure of this drug class is not sufficient for eligibility), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), immunomodulators (IMMs), and/or biologic therapies, as outlined in the protocol. - Subjects must have a documented history of UC for at least 3 months prior to Baseline, confirmed by colonoscopy during the screening period, with exclusion of current infection, colonic dysplasia and/or malignancy. Documentation of pathology results consistent with the diagnosis of UC must be available.

Exclusion Criteria

  • Participants who have had a major surgery performed within 12 weeks prior to Baseline or planned during the conduct of the study (e.g., inguinal hernia repair, cholecystectomy, intestinal resection). - Participants who have concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study treatment, or would put the subject at risk by participating in the study.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
PK Cohort 1: SS1 		Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2
  • Drug: Risankizumab
    Risankizumab intravenous (IV) infusion
    Other names:
    • ABBV-066
Experimental
PK Cohort 1: SS2 Dose A 		Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 1: SS2 Dose B 		Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 1: SS3 Dose A 		Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 1: SS3 Dose B 		Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 2: SS1 		Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
  • Drug: Risankizumab
    Risankizumab intravenous (IV) infusion
    Other names:
    • ABBV-066
Experimental
PK Cohort 2: SS2 Dose A 		Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 2: SS2 Dose B 		Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 2: SS3 Dose A 		Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
PK Cohort 2: SS3 Dose B 		Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
Expansion Cohort 3: SS1 		Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.
  • Drug: Risankizumab
    Risankizumab intravenous (IV) infusion
    Other names:
    • ABBV-066
Experimental
Expansion Cohort 3: SS2 Dose A 		Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
Expansion Cohort 3: SS2 Dose B 		Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
Expansion Cohort 3: SS3 Dose A 		Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066
Experimental
Expansion Cohort 3: SS3 Dose B 		Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
  • Drug: Risankizumab
    Risankizumab subcutaneous (SC) injection
    Other names:
    • ABBV-066

Recruiting Locations

Phoenix Children's Hospital /ID# 273015
Phoenix 5308655, Arizona 5551752 85016

Childrens Center For Digestive Health Care /ID# 273228
Atlanta 4180439, Georgia 4197000 30342

Patewood Medical Campus /ID# 272477
Greenville 4580543, South Carolina 4597040 29615

More Details

Status
Recruiting
Sponsor
AbbVie

Study Contact

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com